# This is a Study to Evaluate the Safety and Tolerability of ABL503, and to Determine the Maximum Tolerated Dose (MTD) and Recommended Phase 2 Dose (RP2D) of ABL503 in Subjects with Any Progressive Locally Advanced or Metastatic Solid Tumors

> **NCT04762641** · PHASE1 · RECRUITING · sponsor: **ABL Bio, Inc.** · enrollment: 100 (estimated)

## Conditions studied

- Advanced Solid Tumor

## Interventions

- **DRUG:** ABL503

## Key facts

- **NCT ID:** NCT04762641
- **Lead sponsor:** ABL Bio, Inc.
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE1
- **Study type:** INTERVENTIONAL
- **Status:** RECRUITING
- **Start date:** 2021-04-01
- **Primary completion:** 2025-11-30
- **Final completion:** 2026-06-15
- **Target enrollment:** 100 (ESTIMATED)
- **Last updated:** 2025-02-06


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT04762641

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT04762641, "This is a Study to Evaluate the Safety and Tolerability of ABL503, and to Determine the Maximum Tolerated Dose (MTD) and Recommended Phase 2 Dose (RP2D) of ABL503 in Subjects with Any Progressive Locally Advanced or Metastatic Solid Tumors". Retrieved via AI Analytics 2026-07-06 from https://api.ai-analytics.org/clinical/NCT04762641. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*